Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immunity, Humoral Clear all

Conditions: Influenza
Interventions: Blood Draw; Procedure
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Pneumococcal Polyvalent Vaccine; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 79 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy
Interventions: pneumococcal vaccination (Pneumovax); Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1980 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: inactivated split-virus influenza vaccine; Biological
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Viral Vaccines, Chikungunya Fever, Chikungunya Virus Infection
Interventions: VRC-CHKVLP059-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: VAX102; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atherosclerosis, Chlamydia Infections, Cytomegalovirus Infections, Pneumonia, Bacterial, Postmenopause
Interventions: Estrogen therapy; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Acne Vulgaris
Interventions: Study of humoral immunity; Diagnostic Test
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Human Papilloma Virus, Anal Dysplasia, HIV
Interventions: Human papillomavirus (HPV) vaccine, 9-valent; Biological
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Primary Immune Deficiency Disorder
Interventions: RI-002; Biological
Lead sponsor: ADMA Biologics, Inc.; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 9
States / cities: Cenntennial, Colorado • North Palm Beach, Florida • Atlanta, Georgia + 5 more

Conditions: Secondary Immune Deficiency Disorder
Interventions: Hizentra; Drug
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
Interventions: Prevnar, Pneumovax; Biological
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza, Influenza Immunisation
Interventions: Influenza Virus Vaccine Inactivated; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: XLA, CVID, Yao Syndrome, Blau Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1990
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis B, Chronic Hepatitis B
Interventions: Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: HIV gp120/NefTat/AS02A Vaccine; Biological
Lead sponsor: Marcus Altfeld, M.D., Ph.D.; Individual
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza, Human
Interventions: Seasonal influenza vaccine; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Immunologic Tests
Interventions: Serum samples; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 64 Years
Enrollment: 414 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions: Tetanus; Biological
Lead sponsor: Robert Krance; Other
Eligibility: 3 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Respiratory Syncytial Virus Infections
Interventions: Adjuvanted RSVPreF3 vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Lexington, Kentucky • St Louis, Missouri • Omaha, Nebraska + 3 more

Conditions: Influenza
Interventions: Trivalent Subviron Influenza vaccine (Fluzone); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Hodgkin's Lymphoma
Interventions: rituximab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 40 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 7
States / cities: Los Angeles, California • Honolulu, Hawaii • Urbana, Illinois + 4 more

Search by objective public record fields.

Immunogenicity of Influenza Vaccine in Long Term Care

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine

Studies of In Vitro B Lymphocyte Responses in Subjects Receiving Tetanus Toxoid Booster Immunization

Influenza Vaccination in Bone Marrow Transplantation

Chikungunya Virus Vaccine Trial in Healthy Adults

Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults

Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Acne Vulgaris Related Microbiology and Serology

Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

Humoral Determinants of Immunity to Pneumococcal Infection

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)

TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

Influenza Vaccine in Pediatric Transplant Subjects

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma